Novo Nordisk share: Deutsche Bank Research deletes buy rating and cuts price target
Deutsche Bank Research has lowered the price target for Novo Nordisk from 400 to 275 Danish kroner after Cagrisema’s study failure and downgraded the shares from “Buy” to “Hold”. Novo…
